Skip to main content

Internationally-recognized ‘We invest in people’ award is certified recognition of the Company’s care and commitment to its employees globally.

Gold IIP Award

Cambridge, UK, 14 June, 2024: Sphere Fluidics, a leading provider of innovative microfluidics-based solutions for single-cell analysis and isolation, today announced that it has received the ‘We invest in people’ Gold accreditation, a prestigious award presented by Investors in People (IIP). This accolade is in recognition of the Company’s commitment to excellence in people management and continuous improvement in workplace practices.

The IIP framework is a globally-recognized standard for people management, defining what it takes to lead, support, and manage people effectively to achieve sustainable results. Presentation of the Gold accreditation signifies how Sphere Fluidics has not only met but surpassed the high standards set by IIP when assessing the Company’s practices, policies overall approach to investment in people. The award demonstrates an outstanding commitment to empowering employees, fostering an inclusive culture, and driving performance through effective leadership and management practices.

Sphere Fluidics has always placed a high priority on the well-being and development of its employees, understanding that a motivated and engaged workforce is essential for driving innovation and achieving strategic goals. This prestigious award is a reflection of the Company’s robust HR practices, including comprehensive professional development programs, a strong emphasis on work-life balance, and an inclusive, collaborative workplace environment. For more information, you can read our company commitment, promise and values on the about us page.

Dale Levitsky, CEO of Sphere Fluidics, expressed his pride in the achievement:

“Receiving the Gold Investors in People Award is a significant milestone for Sphere Fluidics. It recognizes the dedication and hard work of our entire team in creating a workplace where people feel valued, supported, and empowered to reach their full potential. This award is not just a tribute to our HR practices, but a testament to our commitment to nurturing a culture of excellence and continuous improvement.”

Denise Emsden, VP of People & Organizational Development, Sphere Fluidics added:

“We are extremely proud to receive this award; a reflection of the dedication to our team and desire to ensure Sphere Fluidics is a great place to work for all our employees. It’s an honor to receive this recognition of our commitment and ambition to deliver important benefits and support to our team.”

 

To find out more about Investors in People, please visit: Investorsinpeople.com

For further information please contact:

Dr Claire Cox
Sphere Fluidics Ltd.
Tel: +44 (0)7365 209 441
Email: claire.cox@spherefluidics.com  

Zyme Communications
Lily Jeffery
Tel: +44 (0)7891 477 378
Email: lily.jeffery@zymecommunications.com  

About Sphere Fluidics

Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems to enable researchers to find, analyze and isolate the most valuable cells, with ease and speed. 

Sphere Fluidics’ proprietary picodroplet microfluidic platforms are designed specifically for single-cell screening and isolation, allowing users to encapsulate and analyze single cells within a picodroplet, while maintaining viability. Harnessing this technology, the Company’s range of novel microfluidic tools facilitate leading-edge research and accelerate biotherapeutic discovery and development, cell therapy, and synthetic biology workflows, streamlining the journey of discovery in labs, globally. 

Sphere Fluidics is based at Granta Park in Cambridgeshire (UK). The Company has also internationalized its business via a global network of distributors. 

For further information contact:

news icon

Stay ahead with Sphere Fluidics

Join our community of forward-thinking scientists and stay informed with the latest breakthroughs, product launches, and exclusive offers. By subscribing to our newsletter, you'll be the first to know about innovations that can transform your lab.

You may also like